MediWound (NASDAQ:MDWD) COO Sells $51,137.36 in Stock

Posted by Stanley Muller on Aug 28th, 2026

MediWound Ltd. (NASDAQ:MDWD – Get Free Report) COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shmuel Hess also recently made the following trade(s):

On Wednesday, August 26th, Shmuel Hess sold 1,865 shares of MediWound stock. The stock was sold at an average price of $13.00, for a total value of $24,245.00.

MediWound Trading Down 4.4%

MDWD stock traded down $0.58 during midday trading on Friday, hitting $12.66. 165,534 shares of the company’s stock were exchanged, compared to its average volume of 92,786. MediWound Ltd. has a 1-year low of $12.52 and a 1-year high of $20.30. The stock has a market capitalization of $162.71 million, a PE ratio of -7.03 and a beta of 0.15. The business has a 50-day simple moving average of $14.19 and a two-hundred day simple moving average of $15.66.

MediWound (NASDAQ:MDWD – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The business had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. As a group, research analysts expect that MediWound Ltd. will post -2.31 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

Several institutional investors have recently bought and sold shares of the company. Kotler Kevin purchased a new stake in MediWound during the fourth quarter worth about $6,225,000. Millennium Management LLC boosted its stake in shares of MediWound by 355.6% in the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after purchasing an additional 136,884 shares during the period. UBS Group AG boosted its stake in shares of MediWound by 90.1% in the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock valued at $2,678,000 after purchasing an additional 68,756 shares during the period. Sphera Funds Management LTD. grew its holdings in shares of MediWound by 24.3% in the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after purchasing an additional 45,077 shares in the last quarter. Finally, Summit Financial LLC grew its holdings in shares of MediWound by 200.1% in the fourth quarter. Summit Financial LLC now owns 47,998 shares of the biopharmaceutical company’s stock valued at $886,000 after purchasing an additional 32,006 shares in the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MDWD has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of MediWound in a research report on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. Finally, Oppenheimer reissued an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $33.00.

Check Out Our Latest Research Report on MediWound

MediWound Company Profile

(Get Free Report)

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.